Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis

被引：0
|
作者：
Thomas Wilke
Sabrina Mueller
Andreas Fuchs
Margit S. Kaltoft
Stefan Kipper
Malgorzata Cel
机构：
[1] Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM) an der Hochschule Wismar,Global Development
[2] Ingress-Health,undefined
[3] AOK PLUS,undefined
[4] Novo Nordisk A/S,undefined
[5] Novo Nordisk Pharma GmbH,undefined
[6] Novo Nordisk Region Europe,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Claims data; Cost; Effectiveness; Germany; Insulin; Liraglutide; Propensity score; Real-world; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2357 / 2370
页数：13
相关论文
共 50 条
  • [1] Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis
    Wilke, Thomas
    Mueller, Sabrina
    Fuchs, Andreas
    Kaltoft, Margit S.
    Kipper, Stefan
    Cel, Malgorzata
    DIABETES THERAPY, 2020, 11 (10) : 2357 - 2370
  • [2] Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus
    Bruinstroop, Eveline
    Meyer, Laura
    Brouwer, Catherine B.
    van Rooijen, Diana E.
    van Dam, P. Sytze
    DIABETES THERAPY, 2018, 9 (03) : 1369 - 1375
  • [3] Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus
    Eveline Bruinstroop
    Laura Meyer
    Catherine B. Brouwer
    Diana E. van Rooijen
    P. Sytze van Dam
    Diabetes Therapy, 2018, 9 : 1369 - 1375
  • [4] Insulin Prescription Rate and Diabetes-Related Complications in Mexican Patients with Type 2 Diabetes
    Lizet Quintanilla-Flores, Dania
    Analy Velez-Viveros, Claudia
    Portillo-Sanchez, Paola
    Marisol Santos-Santillana, Karla
    Cesar Solis-Pacheco, Ricardo
    Rodriguez-Gutierrez, Rene
    DIABETES, 2017, 66 : A659 - A659
  • [5] Analysis of the Incidence of Type 2 Diabetes, Requirement of Insulin Treatment, and Diabetes-Related Complications among Patients with Cancer
    Lee, Su Jung
    Kim, Chulho
    Yu, Hyunjae
    Kim, Dong-Kyu
    CANCERS, 2023, 15 (04)
  • [6] COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS INSULIN GLARGINE IN CHINESE PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED ON METFORMIN
    Gu, X.
    Liu, F.
    Men, P.
    Zhai, S.
    VALUE IN HEALTH, 2018, 21 : S75 - S75
  • [7] Diabetes-related Distress in Korean Patients with Type 2 Diabetes
    Kim, So Hun
    Han, Ju Young
    Hong, Seong Bin
    Kim, Yong Seong
    Nam, Moon-Suk
    DIABETES, 2015, 64 : A233 - A234
  • [8] PREDICTORS OF GLYCEMIC CONTROL AND DIABETES-RELATED COSTS AMONG ADULT TYPE 2 DIABETES PATIENTS INITIATING THERAPY WITH LIRAGLUTIDE
    Durden, E.
    Lenhart, G.
    Lopez-Gonzalez, L.
    Hammer, M.
    Langer, J.
    VALUE IN HEALTH, 2015, 18 (03) : A54 - A54
  • [9] 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine
    Niu, Shu
    Alkhuzam, Khalid A.
    Guan, Dawei
    Jiao, Tianze
    Shi, Lizheng
    Fonseca, Vivian
    Laiteerapong, Neda
    Ali, Mohammed K.
    Schatz, Desmond A.
    Guo, Jingchuan
    Shao, Hui
    DIABETES OBESITY & METABOLISM, 2024, 26 (02): : 463 - 472
  • [10] Cost Predictors in Type 2 Diabetes Mellitus: A Retrospective Claims Database Analysis
    Bron, Morgan
    Guerin, Annie
    Latremouille-Viau, Dominick
    Ionescu-Ittu, Raluca
    Samp, Jennifer
    Wu, Eric
    DIABETES, 2013, 62 : A324 - A324
12345